Skip to main content

Advertisement

Achromobacter spp. healthcare associated infections in the French West Indies: a longitudinal study from 2006 to 2016

Abstract

Background

Bacteria of the Achromobacter genus, more particularly xylosoxidans species, are responsible for various healthcare associated infections (HAI) which are increasingly described since the last decade. Cystic fibrosis (CF) patients are considered as potential reservoirs in hospitals. We performed a retrospective study to estimate the frequencies of Achromobacter spp. HAI among patients from French West Indies, to determine characteristics of infected patients and establish a possible link between CF and infections.

Methods

All adults with at least one Achromobacter spp. positive sample and infection criteria in accordance with European official definitions of HAI, hospitalized in University Hospital of Martinique from 2006 to 2016 for more than 48 h, were included. Patient clinical features, immune status and underlying diseases were obtained from medical files. A list of CF patients was given by clinicians.

Antibiotic-susceptibility profiles of the strains were determined using an automated method.

Results

Mean incidence density was 0.038/1000 days of hospitalization. Achromobacter spp. HAI evolved as an endemic situation with a low but pretty much stable incidence rate over the 11-year observation period. An epidemic peak was noticed in 2013. Among the 66 included patients, 56.1% were immunocompetent and no one had CF. Pneumonia and bacteraemia were the two main HAI. Among the 79 isolated strains, 92.4% were resistant to at least 1 major antibiotic and 16.4% met the definition of multidrug-resistant bacteria.

Conclusions

This microorganism, little known in our country because of the scarcity of CF patients, represents a threat for both immunosuppressed and immunocompetent patients and a therapeutic challenge because of its high resistance.

Background

Achromobacteria, multiresistant opportunistic hydro-telluric pathogens, are emerging in hospital environments [1]. The most frequently encountered species is Achromobacter xylosoxidans which has been found in various contaminated solutions in hospitals, such as dialysis water, demineralized water, water from nebulizers, humidifiers, incubators, extracorporeal circulation systems, poorly preserved heparin flasks and even antiseptic and disinfectant solutions because of an increasing acquired resistance to these products [2,3,4]. Its preferential temperature of growth is 30 °C, which makes it particularly adapted to tropical climate.

Research on Achromobacter began in the early 1970s, stagnated for 10 years and has increased exponentially over the last decade in parallel with the rise of related HAI [5]. However, clinicians remain poorly informed and more often consider these bacteria as contaminants [6].

Achromobacter, most notably xylosoxidans, is known to colonize the respiratory tract of CF patients and most authors reported its increased prevalence in that population [7,8,9], who might represent the microorganism’s main human reservoir in healthcare facilities where cross-contaminations have been described [8, 9]. Various Achromobacter HAI have been reported, especially in ophthalmology [10], pulmonology [1, 6], surgery [11,12,13] mainly documented by case reports [3, 11,12,13,14,15,16,17] or clustered cases of infections during small outbreaks [18,19,20]. But, to our knowledge, only three retrospective studies are available and they all focused on targeted pathologies: two evaluated respectively 54 and 13 bacteraemia in a 10 -year observational period in Spain [21, 22] and one concerned 41 pneumonia in the elderly in China [6]. None gave a detailed inventory of the different types of HAI.

Infections related to these bacteria are considered mainly associated to an immunocompromised status [3, 14, 18, 20]. However, numerous cases of Achromobacter infection occurring in immunocompetent patients have been published [11, 12, 15, 16].

The main objective of our study was to estimate frequencies and distribution of Achromobacter spp. HAI among all adults hospitalized in the University Hospital of Martinique between 2006 and 2016. The secondary goals were to describe characteristics of infected patients, particularly their immune status, and to establish a possible link between such infections and CF.

Methods

Design

We performed a retrospective monocenter study from January 2006 to December 2016 based on original data extracted from our Bacteriology Laboratory database (SIRweb™, i2a, Montpellier, France) in a listing of all Achromobacter spp. positive clinical samples analyzed.

The study was conducted in the University Hospital of Martinique, a 1484-bed public facility resulting from the merger of 7 sites. Our team of 3 physician-hygienists and 5 nurse-hygienists monitors HAI throughout the whole institution.

Study population

We included all adults (> 18 years old) hospitalized between January 1st 2006 and December 31th 2016 in the largest site of our institution, Pierre-Zobda-Quitman1 Hospital, including 35 medical and surgical units (570 beds).

Inclusion criteria were patients with ≥1 clinical isolate positive for Achromobacter spp. with associated clinical, radiological, biological criteria in accordance with European Union case definitions [23], regardless of the type of infection. Samples were taken into account only if they were qualitatively and quantitatively consistent with the microbiological criteria [23] and if the infection was confirmed by clinicians. Only patients with HAI were included. Cases were considered as HAI when infection occurred more than 48 h after admission, as defined by the European Union [23]. Conversely, patients whose infections occurred less than 48 h post-admission, considered as community cases, were excluded from the study, as well as positive samples corresponding to colonizations.

Duplicates, i.e. strains with the same antimicrobial susceptibility isolated from the same sample type from a given patient, were excluded.

Data sources

Data collected concerned basic demographics (sex, age), patient stay (admission date, unit), sample characteristics (specimen type, time of positive culture, concomitant microorganisms (same specimen), and antibiotic susceptibility), HAI criteria and validation by clinician, iatrogenic causes of immune deficiency (immunosuppressants, chemotherapy, radiotherapy, organ transplantation, glucocorticoids), CF and/or other relevant underlying or autoimmune diseases, presence of invasive medical device (intra-vascular devices, prothesis, implants, intubation, urinary tract catheter …). Ventilator-associated pneumonia and catheter-related bacteraemia were defined according to the European Union criteria [23].

Demographics, patient stay and sample data were extracted from SIRweb™. Financial Services provided the number of admissions and patient-bed days.

Clinical, biological and radiological criteria of Achromobacter spp. HAI and underlying diseases were obtained from consulting medical files or from a coding software for medical procedures linked to hospitalization and operative reports (CORA software-Maincare Solutions, Cestas, France).

A list of CF patients followed from 2006 to 2016 was provided by the clinicians from the Department of Pulmonology.

Patients meeting one of the following criteria described in our Nosocomial Infections National Prevalence Survey (NINPS) protocol [24] were considered immunocompromised: i.e., solid tumor or hemopathy, organ transplantation, radiotherapy, chemotherapy, immunosuppressive therapy, high-dose prednisolone (> 5 mg/kg/day) or prolonged (> 30 days) corticosteroid use or Human Immunodeficiency Virus infection with < 500 CD4+ cells/mm3. The immunocompromised status was established from the following data: history of organ transplantation (provided by clinicians), chemotherapy, radiotherapy or immunosuppressive therapy from 2006 to 2016 (provided by pharmacists and Medical Information Department), and the existence of co-morbidities requiring long-term general corticosteroid therapy (provided by CORA software).

Microorganisms and antibiotic susceptibility

Methods remained consistent along the 11-year period of the study. Strains isolated from biological samples were first identified with the API 20NE system (bioMerieux, Marcy-l’Etoile, France). Confirmation was performed later by MALDI-TOF (Microflex LT, Brüker, Germany) on the preserved strains. One strain was identified using nrdA sequencing [25].

Antibiotic-susceptibility profiles were determined using the automated Microscan Walkaway® system (Beckman Coulter, Villepinte, France) with NEG Urine combo panel type 57 micro-plates. Briefly, a micro-inoculum taken from a bacterial colony using the Prompt Inoculation System-D was suspended in saline buffer (0.5 McFarland Standard). The suspension was used to inoculate a 96-well plate coated with standard biochemical indicators and antibiotics. The plate was incubated at 37 °C for 24 h and bacterial growth was determined by measuring the optical density at 600 nm. This technique enables bacterial identification and minimal inhibitory concentration (MIC) calculation. Six major antibiotics were tested (i.e., main molecules usually used to treat Achromobacter infections) [3, 8]. They are cited in Table 4.

Resistant strains were defined as strains able to become resistant to one or several antimicrobial agents used for therapy or prophylaxis, according to the European Center for Diseases prevention and Control [26]. Multidrug-resistant (MDR) strains were defined as non-susceptible to at least one agent in > 3 different antimicrobial categories, according to the International Expert Proposal and considering data from Pseudomonas aeruginosa [27].

Strains exhibiting intermediate or strong resistance to the tested molecule were considered resistant, as defined in the NINPS protocol [24]. Resistance rate for one given antibiotic was calculated as follows: ((total number of isolated strains - susceptible strains) / total number of isolated strains) X 100, as described in our National Surveillance of Antibiotic Consumption protocol [28].

Statistical analyses

Incidence was defined as number of new cases during a period/number of hospitalized patients during the same period. Incidence density was defined as number of new cases during a period/number of days of hospitalization during the same period.

Categorical data, expressed as numbers and percentages, were compared with χ2 or Fisher’s exact test, and quantitative data, expressed as means +/− standard deviation (SD), were compared using Student’s t-test. Analysis was performed using SAS /STAT software (SAS, France). Significance was defined as p < 0.05.

Results

Study population

The SIRweb™ database initially yielded 107 Achromobacter spp-positive clinical isolates. All were identified as Achromobacter xylosoxidans.

After applying inclusion and exclusion criteria, our dataset included 79 positive clinical isolates, corresponding to 66 patients and 69 HAI (one patient may have more than one positive clinical isolate and may develop more than one HAI). Details are given by the study flow chart (Fig. 1).

Fig. 1
figure1

Study flow chart. 135 positive samples extracted from laboratory data base; application of exclusion criteria; 79 resulting included cases = 69 HAI = 66 patients

Basic demographics are shown in Table 1. Patients with Achromobacter spp. HAI were predominantly men. Their mean age was 61.5 +/− 17.7 years, with 53% of them < 65 years old, but women were 10.8 years older than men (p = 0.01).

Table 1 Demographics and clinical features of 66 the patients with Achromobacter spp. HAI

Frequencies

The mean annual incidence (pooled mean of all cases) was 1.45/10,000 patients (95% confidence interval (CI) ± 0.52). The mean incidence density (pooled mean of all cases) was 0.038/1000 days of hospitalization (95% CI ± 0.011).

Figure 2 describes the time-line distribution of annual incidence densities. A global stability of annual incidence densities was observed, with an epidemic peak in 2013. It showed a tendency to decrease over the last 3 years.

Fig. 2
figure2

Time-line distribution of annual incidence densities. Annual incidence densities = number of new cases during the year/number of days of hospitalization during the same year

The 66 included cases were pooled in order to study a possible seasonal variability. The monthly distribution of included cases is represented by Fig. 3. The highest number of cases was observed in February, with two other maximum in May–June and August. On the other hand, the same number of cases were diagnosed whatever the season, 34 cases during dry season (November to April, temperature around 27 °C humidity around 65% and little rain) and 32 during cyclonic season (May to October, temperatures around 31 °C humidity up to 80% and heavy rainfall).

Fig. 3
figure3

Monthly distribution of included cases (pooled data). 66 included cases from 2006 to 2016 pooled and expressed as number of cases per month of diagnosis

Patients’ clinical features and infections

Patients’ clinical features are described in Table 1. Table 2 gives the distribution of the 69 HAI. HAI were diagnosed within an average of 23 days, with extreme values ranging from 4 to 94 days. Most HAI occurred in medical units, the most common being pneumonia (37.7%) and bacteraemia (33.3%).

Table 2 Distribution of the 69 HAI

The bacteriological diagnosis of Achromobacter spp. pneumonia, in addition to the clinical, biological and radiological criteria, was based on positive quantitative culture of distal protective aspirates (n = 11), broncho-alveolar lavage (n = 12) and endotracheal aspirates (n = 3). According to the European Union classification, 23 cases were defined as PN1 and 3 as PN2 (i.e. certain (PN1) or probable (PN2) pneumonias with clinical and radiological elements, associated with microbiological documentation).

Among the 66 patients included, 36 had mechanical ventilation at least 48 h before the diagnosis. Achromobacter spp. pneumonia acquisition was very significantly higher among those patients than among patients without mechanical ventilation, who developed more particularly other types of Achromobacter spp. HAI (χ2, p = 0.0002). Cardiovascular pathologies were the main underlying diseases among patients with pneumonia (n = 8).

All patients with Achromobacter spp. bacteraemia presented clinical signs of sepsis. 60.8% (n = 14) had catheter-related infections. Other sources were surgical site infections (n = 4), and urinary tract infection (n = 1). Four patients had no identifiable source of bacteraemia. Cancers (solid tumor + malignant hemopathy) (n = 12) and cardiovascular pathologies (n = 6) were the main underlying diseases among patients with bacteraemia.

Intra-abdominal infections were peritonitis (n = 5) and hepatic abscesses following surgery (n = 2). All were diagnosed on positive cultures of purulent material from intra-abdominal space obtained during surgical revision (n = 2) or liquid puncture (n = 5).

All urinary tract infections were microbiologically confirmed symptomatic infections.

Among the 69 Achromobacter spp. HAI, 6 occurred after surgery and met the definition of surgical site infections. One was superficial (wound infection) and 5 were deep infections (3 mediastinitis and 2 deep abscesses).

NINPS criteria for immunocompromised status were met by only 43.9% of the patients. 33.3% of included patients had cancer.

None of the patients had CF, both among included patients and among patients having a simple colonization, excluded from the study.

Microorganisms and antibiotic susceptibility

Another microorganism was isolated from 24.1% of the 79 samples as described in Table 3.

Table 3 Co-infecting pathogens and resistant rates of the 79 clinical isolates

Ten pneumonia (38%), 4 bacteraemia (17%), 4 intra-abdominal infections (57%) and 1 mediastinitis (33%) were polymicrobial. The most frequent co-infecting microbes were Pseudomonas aeruginosa (23%), Klebsiella pneumoniae (16%), Candida albicans (16%), Stenotrophomonas maltophilia (13%) and Staphylococcus aureus (10%). P. aeruginosa and C. albicans were mainly found in lower respiratory tract specimens, while K. pneumoniae could be isolated from all types of Achromobacter spp-positive samples.

Antibiotic-susceptibility profiles of Achromobacter spp. isolates are reported in Table 4.

Table 4 Antibiotic-susceptibility profiles of the 79 isolated strains

Strains were more susceptible to Trimethoprim + Sulfamethoxazole, Ticarcillin + Clavulanic acid and Imipenem.

Seventy three out of the 79 isolated strains (92.4%) were resistant to one or more major antibiotics (Table 3). Only 6 strains were susceptible to all tested molecules and 13 strains (16.4%) met the definition of MDR strains, including 3 blood samples (13%). Among those 13 MDR strains, a lower respiratory sample from a 39-year-old immunocompromised woman with acquired immunodeficiency syndrome yielded a strain resistant to all antibiotics tested.

All the 6 susceptible strains were isolated in patients hospitalised before 2012 and most MDR were isolated after 2013 (n = 9), suggesting an increase in the resistance of the strains during the observation period.

Discussion

Our study showed that an average of 1.15/10,000 patients a year has developed Achromobacter spp. HAI in our institution from 2006 to 2016. Those infections, especially pneumonia or bacteraemia, appeared within an average 23-days hospitalization period.

Infected patients were predominantly men, relatively young, with cardiovascular pathologies and mostly immunocompetent. These Achromobacter spp. HAI were not related to CF, none of our included patient being affected by this pathology.

In all isolates analysed, only one and the same species, Achromobacter xylosoxydans, was identified. However, the methods used for identification were not the recommended method to distinguish species, i.e., nrd A sequencing [29], so, all isolates were referred as Achromobacter spp.

Since 2011, our institution regularly conducts an annual national surveillance of HAI in intensive care unit [30]. The mean annual incidence over the last 7 years is 20/100 patients (including all infections and all microorganisms). Ventilator associated pneumonia (VAP) and catheter-related bacteraemia are the most common infections and Klebsiella pneumoniae is the most frequently encountered bacteria.

In our study, although the annual incidence of Achromobacter spp. HAI was fairly low, it remained pretty much stable over the 11-year observation period, meaning that Achromobacter spp. HAI evolved as an endemic situation. Only one epidemic peak was observed in 2013. That year, our institution was merged with 2 other sites to create the University Hospital of Martinique. Well known organizational disorders generated by this event may probably explain a global and transient loosening of good hygiene practices. When compared to the results of our annual surveillance in intensive care unit [30], we note stable infection rates (26.4% in 2012, 26.6% in 2013) but an increase in Pseudomonas aeruginosa infections (22.6% of total isolated germs in 2013 versus 4.8% in 2012). The merger had a low impact on the activity and behaviour of healthcare workers in intensive care unit because they were already used to receive patients from all other sites, but it is likely that the loosening of good hygiene practices mainly concerned environment management in the whole institution. Despite a slight decrease in incidence of Achromobacter spp. HAI at the end of the study, we observed an increase in 2017 (0.037/1000 days of hospitalization).

Half of the cases in this study were diagnosed in February, May–June and August (n = 33). Surprisingly, these months represent vacation periods, with carnival days in February, a succession of public holydays in May and June and summer holidays in August. The lack of staff or the use of substitute staff during these periods may explain once again a loosening of good hygiene practices. Contrary to what we might think, Achromobacter spp. HAI seem to be linked more to human behavior than to climatic conditions. In fact, no seasonal variation could be demonstrated. A recent retrospective study on Achromobacter xylosoxidans colonizations in young children with CF contradicts our observations, showing a seasonal variation in acquisition of the bacteria, with a peak incidence in the winter. The authors explain it by higher prevalence of viral respiratory infections in the winter increasing airway susceptibility to bacterial colonization. However, it is the only study available dealing with seasonality and Achromobacter, in a context very far from our own in terms of population, pathologies and climate [31].

Because of the low incidence of Achromobacter spp. HAI, we decided to undertake a retrospective study. Knowing that susceptibility to infections, response to antibiotics, clinical features and outcomes differ between children and adults, we considered only adult cases. The availability of data extracted from SIRweb™ software set the inclusion period at 11 years, which identified only 66 patients, a relatively small population. Analyses of different variables generated small subgroups among them, making statistical comparisons difficult if not impossible.

Old age (> 65 years) does not seem to favor infections in the studied population. Indeed, average age was similar to that of all hospitalized patients (61.9 years in 2016) and did not exceed 65 years. Because most studies targeted specific populations (newborns, elderly …), available published information is insufficient to compare and/or confirm our results.

One of the main findings of our study is that there is no link between Achromobacter spp. HAI and CF patients. Because of ethnic specificities, CF is very scarce in Martinique. Only 39 patients were followed for CF from 2006 to 2016. Among these patients, none was included in our study and none was even colonized by Achromobacter spp. While prevalence of Achromobacter spp. in CF patients is 6.3% in Metropolitan France [8], it is 0% in Martinique. So, such patients cannot be a potential human Achromobacter spp. reservoir in our institution. Our series of 26 Achromobacter spp. pneumonias without CF completes published series (32 cases) [1], these 26 cases alone accounting for 45% of total cases published over 40 years.

According to our results, pneumonia represented the main Achromobacter spp. HAI among our patients over the past 11 years in Martinique and those infections do not seem to affect preferentially patients with cancer. Our findings contrast with Swenson and Sadikot’s observations showing a strong relationship between hematological or solid-organ malignancies and Achromobacter spp. pneumonia [1]. Conversely, our results are in accordance with Liu et al who described 41 cases of Achromobacter xylosoxidans pneumonia in the elderly. Only 19.5% had malignancies and cardiovascular pathologies were the main underlying disease [6].

The mechanical ventilation–pneumonia association we found is not specific to Achromobacter spp. HAI. In fact, mechanical ventilation is the major cause of nosocomial pneumonia [32] and concerns 87.4% of cases in France [30]. The high rate of ventilator-associated pneumonia may explain the polymicrobial character of a great number of lower respiratory tract samples from our study. As recently described by Rodrigues et al, bacterial and/or fungal biofilms, most of them being polymicrobial, develop on the surface of endotracheal tubes and represent the starting point for most VAP [33].

Such mechanical ventilation association confirmed the nosocomial character of pneumonia in our study and revived the question about Achromobacter spp. digestive carriage, which remains controversial [7, 11, 14, 34]. Although the gastro-pulmonary route is not considered to be the major route for the development of VAP, gastric colonization remains a potential endogenous source of infection [32]. In fact, a recent study even showed a relationship between digestive tract colonization related to extended-spectrum beta-lactamase producing Enterobacteriaceae (ESBLE) and the occurrence of ESBLE VAP [35]. Achromobacter spp. digestive colonization may occur after ingestion of contaminated drinking water or during ocean/river activities that are very common in Martinique. Moreover, in our study, intra-abdominal pathologies represented both the third underlying disease and the third HAI. We plan to complete this study by identifying natural Achromobacter spp. sources in our environment, especially in rivers, Caribbean Sea or Atlantic Ocean, and by examining potential digestive carriage using rectal swabs.

The second most common Achromobacter spp. HAI in our study was bacteraemia, most being related to catheter. Our 23 cases complete the 13 cases observed by Perez-Barrangan et al in their recent 10-years retrospective study, which was conducted in Spain during the same period [22]. Predominance of catheter-related infections appears more clearly in our study (60.8% versus 30.7%). Both studies highlight similar most common underlying diseases and similar rates of polymicrobial bacteraemia (15 and 17%). Immunocompromised rates could not be compared because it was not clearly determined in the Spanish study. Conversely, the same MDR definition was used and the Spanish isolates seem to show a highest resistance compared to the Martinican ones (38.4% versus 13%).

One of the main features of our population was their low immunocompromised rate. Compared to the literature [3, 14, 18, 20] more than 50% of our patients did not meet the immunosuppression criteria [23]. Achromobacter spp. is classically considered as an opportunistic pathogen, theoretically described as microorganisms mainly infecting immunocompromised individuals. Our findings could question that hypothesis. Moreover, a recent publication defines for the first time both immunosuppressed and immunocompetent populations as potential targets for this bacterium [36].

Larger multicenter studies are needed to enable multivariable analyses to assess potential associations between Achromobacter spp. and the immunocompromised rate.

Conclusions

In Metropolitan France, genus Achromobacter is emerging among CF patients and among immunocompromised patients. In Martinique, it evolves as an endemic situation and seems to affect mainly immunocompetent patients without CF. It appears as neither an innocuous environmental bacterium nor a simple contaminant. It may be a future threat for patient safety in the hospital environment. In vitro experiments and environmental investigations are currently underway in our institution to highlight potential sources of contamination and their portals of entry.

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Abbreviations

CF:

Cystic Fibrosis

CI:

Confidence Interval

ECDC:

European Center for Disease prevention and Control

ESBLE:

Extended-Spectrum Beta-Lactamase producing Enterobacteriaceae

HAI:

Healthcare Associated Infections

MDR:

Multi-Drug Resistant

MIC:

Minimal Inhibitory Concentration

NINPS:

Nosocomial Infections National Prevalence Survey

SD:

Standard Deviation

VAP:

Ventilator-Associated Pneumonia

References

  1. 1.

    Swenson CE, Sadikot RT. Achromobacter respiratory infections. Ann Am Thorac Soc. 2015;12:252–8.

  2. 2.

    Amoureux L, Bador J, Fardeheb S, Mabille C, Couchot C, Massip C, et al. Detection of Achromobacter xylosoxidans in hospitals, domestics and outdoor environmental samples and comparison with human clinical isolates. Appl Environ Microbiol. 2013;79(23):7142–9.

  3. 3.

    Duggan JM, Goldstein SJ, Chenoweth CE, Kauffman CA, Bradley SF. Achromobacter xylosoxidans bacteriemia: report of four cases and review of the literature. Clin Infect Dis. 1996;23:569–76.

  4. 4.

    Fujioka M, Oka K, Kitamura R, Yakabe A, Chikaaki N. Alcaligenes xylosoxidans cholecystitis and meningitis acquired during bathing procedures in a burn unit: a case report. Ostomy Wound Manage. 2008;54(12):48–53.

  5. 5.

    Jeukens J, Freschi L, Vincent AT, Emond-Rheault JG, Kukavica-Ibrulj I, Charette SJ, et al. A pan-genomic approach to understand the basis of host adaptation in Achromobacter. Genome Biol Evol. 2017;9:1030–46.

  6. 6.

    Liu C, Guo J, Yan W, Jin Y, Pan F, Fang X, et al. Hospital-acquired pneumonia due to Achromobacter xylosoxidans in the elderly: a single-center retrospective study in Beijing. J Infect Dev Ctries. 2017;11:10–8.

  7. 7.

    Recio R, Brañas P, Martínez MT, Chaves F, Orellana MA. Effect of respiratory Achromobacter spp. infection on pulmonary function in patients with CF. J Med Microbiol. 2018;67(7):952–6.

  8. 8.

    Amoureux L, Sauge J, Sarret B, Lhoumeau M, Bajard A, Tetu J, et al. Study of 109 Achromobacter spp. Isolates from 9 French CF centers reveals the circulation of a multiresistant clone of A. xylosoxidans belonging to ST137. J Cyst Fibros. 2019. https://doi.org/10.1016/j.jcf.2019.04.005 [Epub ahead of print].

  9. 9.

    Talbot NP, Flight WG. Severe Achromobacter xylosoxidans infection and loss of sputum bacterial diversity in an adult patient with CF. Paediatr Respir Rev. 2016;20(Suppl):27–9.

  10. 10.

    Villegas VM, Emanuelli A, Flynn HW, Berrocal AM, Miller D, Kao AA, et al. Endophthalmitis caused by Achromobacter xylosoxidans after cataract surgery. Retina. 2014;34(3):583–6.

  11. 11.

    Lee JH, Lee SY, Park IY, Park SI, Lee JS, Kang G, et al. A case of septic shock caused by Achromobacter xylosoxidans in an immunocompetent female patient after extracorporeal shock wave lithotripsy for a ureteral stone. J Infect Chemother. 2016;48:47–50.

  12. 12.

    Rafael AE, Keshavamurthy S, Sepulveda E, Miranda CC, Okamoto T, Pettersson GB. Intracardiac abscess with cutaneous fistula. Tex Heart Inst J. 2014;41:324–6.

  13. 13.

    Sawant AC, Srivatsa SS, Castro LJ. Alcaligenes xylosoxidans endocarditis of a prosthetic valve and pacemaker in a 62-year-old woman. Tex Heart Inst J. 2013;40(1):95–8.

  14. 14.

    Enriquez M, Favini A, Curl K. Sustained Achromobacter xylosoxidans bacteriemia in patient with adenocarcinoma of colon. The Medicine Forum. 2013;15:5–7.

  15. 15.

    Eshwara VK, Mukhopadhyay C, Mohan S, Prakash R, Pai G. Two unique presentations of Achromobacter xylosoxidans infections in clinical settings. J Infect Dev Ctries. 2011;5:138–41.

  16. 16.

    Gupta V, Nirkhiwale S, Gupta P, Phatak S. Achromobacter xylosoxidans mesh related infection: a case of delayed diagnosis and management. J Inf Secur. 2012;64:e1–5.

  17. 17.

    Teng SO, Ou TY, Hsieh YC, Lee WC, Lin YC, Lee WS. Complicated intra-abdominal infection caused by extended drug-resistant Achromobacter xylosoxidans. J Microbiol Immunol Infect. 2009;42:176–80.

  18. 18.

    Kim MJ, Bancroft E, Lehnkering E, Donlan RM, Mascola L. Alcaligenes xylosoxidans bloodstream infections in outpatient oncology office. Emerg Infect Dis. 2008;14:1046–52.

  19. 19.

    Haviari S, Cassier P, Dananché C, Hulin M, Dauwalder O, Rouvière O, et al. Outbreak of Achromobacter xylosoxidans and Ochrobactrum anthropi infections after prostate biopsies, France, 2014. Emerg Infect Dis. 2016;22(8):1412–9.

  20. 20.

    Hugon E, Marchandin H, Poirée M, Fosse T, Sirvent N. Achromobacter bacteraemia outbreak in a paediatric onco-haematology department related to strain with high surviving ability in contaminated disinfectant atomizers. J Hosp Infect. 2015;89:116–22.

  21. 21.

    Gómez-Cerezo J, Suárez I, Ríos JJ, Pena P. Garcia de Miguel MJ, de José M, et al. Achromobacter xylosoxidans bacteraemia: a 10-year analysis of 54 cases. Eur J Clin Microbiol Infect Dis. 2003;22:360–3.

  22. 22.

    Pérez Barragán E, Sandino Pérez J, Corbella L, Orellana MA, Fernández-Ruiz M. Achromobacter xylosoxidans bacteremia: clinical and microbiological features in a 10-year case series. Rev Esp Quimioter. 2018;31(3):268–73.

  23. 23.

    Special health issues, nosocomial infections. In: Official Journal of the European Union. Commission implementing decision, 2018/945 on the communicable diseases and related special health issues to be covered by epidemiological surveillance as well as relevant case definitions. http://data.europa.eu/eli/dec_impl/2018/945/oj. Accessed June 2018.

  24. 24.

    Santé Publique France. National prevalence survey of HAI and anti-infective treatments in healthcare facilities. Auditor's Guide [in French]. 2017. http://invs.santepubliquefrance.fr .

  25. 25.

    Marion-Sanchez K, Lion F, Olive C, Cailleaux G, Roques F. Mediastinitis superinfected by Achromobacter xylosoxidans. A case report. J Infect Chemother. 2018;24:987–9.

  26. 26.

    European Center for Diseases Prevention and Control. Antimicrobial resistance and healthcare associated infections programm. https://ecdc.europa.eu/en/about-uswho-we-aredisease-programmes/antimicrobial-resistance-and-healthcare-associated-infections. Accessed 2019.

  27. 27.

    Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–81.

  28. 28.

    Santé Publique France. Réseau ATB-RAISIN. National Surveillance of antibiotic consumption. National protocol [in French]. 2018.

  29. 29.

    Spilker T. Vandamme, LiPuma JJ. A multilocus sequence typing scheme implies population structure and reveals several putative novel Achromobacter species. J Clin Microbiol. 2012;50(9):3010–5.

  30. 30.

    Santé Publique France. Réseau REA-RAISIN. Monitoring HAI in intensive care units. Results [in French]. 2017 http://invs.santepubliquefrance.fr/Publications-et-outils/Rapports-et-syntheses/Maladies-infectieuses/2019/Surveillance-des-infections-nosocomiales-en-reanimation-adulte

  31. 31.

    Psoter KJ, De Roos AJ, Wakefield J, Mayer JD, Rosenfeld M. Seasonality of acquisition of respiratory bacterial pathogens in young children with CF. BMC Infect Dis. 2017;17(1):411.

  32. 32.

    Joseph MN, Sistla S, Dutta TK, Badhe AS, Parija SC. Ventilator-associated pneumonia: a review. Eur J Intern Med. 2010;21(5):360–8.

  33. 33.

    Rodrigues ME, Lopes SP, Pereira CR, Azevedo NF, Lourenço A, Henriques M, et al. Polymicrobial ventilator-associated pneumonia: fighting in vitro Candida albicans-Pseudomonas aeruginosa biofilms with antifungal-antibacterial combination therapy. PLoS One. 2017. https://doi.org/10.1371/journal.pone.0170433.

  34. 34.

    Chang JM, McCanna DJ, Subbaraman LN. Efficacy of antimicrobials against biofilms of Achromobacter and Pseudomonas. Optom Vis Sci. 2015;92:506–13.

  35. 35.

    Houard M, Rouze A, Ledoux G, Six S, Jaillette E, Julien Poissy J, et al. Relationship between digestive tract colonization and subsequent ventilator associated pneumonia related to ESBL producing Enterobacteriaceae. PLoS One. 2018;13(8). https://doi.org/10.1371/journal.pone.0201688.

  36. 36.

    Awadh H, Mansour M, Aqtash O, Shweihat Y. Pneumonia due to a rare pathogen: Achromobacter xylosoxidans, subspecies denitrificans. Case Rep Infect Dis. 2017;2017:3969682. https://doi.org/10.1155/2017/3969682.

Download references

Acknowledgements

We are grateful to Mrs. Janet Jacobson for editorial assistance and to Dr. Emmanuelle Sylvestre from the department of medical information, CHU Martinique, for her scientific advice.

Ethics approvals and consent to participate

This study was approved for its compliance to ethical standards by the Institutional Review Board of the University Hospital of Martinique (reference number 2019–004). Procedures applied in the study were in accordance with the Helsinki Declaration.

A statement was made to the French data protection authority (CNIL).

A verbal consent to participate was obtained from the patients or their family after reading an information letter. In fact, according to French law, in the context of a non-interventional retrospective study, written consent is not required.

Funding

This work was supported by the Department of Clinical Research of the University Hospital of Martinique. Funds were used especially for study design, data analyses and publication fees.

Author information

KMS and CD conceived and designed the study. KMS, KP and CO collected the data and CD analyzed the data. KMS, KP, CO, CD interpreted the data. KMS wrote the first draft of the manuscript. CD and XLC reviewed the final report. All authors read and approved the final version of the manuscript.

Correspondence to Karine Marion-Sanchez.

Ethics declarations

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Keywords

  • Achromobacter spp., healthcare associated infection
  • Immunocompetent
  • Resistance, retrospective study